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AU-rich element mRNA-binding proteins (AUBPs) are key regula-
tors of development, but how they are controlled and what
functional roles they play depends on cellular context. Here, we
show that Brf1 (zfp36l1), an AUBP from the Zfp36 protein family,
operates downstream of FGF/Erk MAP kinase signaling to regulate
pluripotency and cell fate decision making in mouse embryonic
stem cells (mESCs). FGF/Erk MAP kinase signaling up-regulates
Brf1, which disrupts the expression of core pluripotency-associ-
ated genes and attenuates mESC self-renewal without inducing
differentiation. These regulatory effects are mediated by rapid
and direct destabilization of Brf1 targets, such as Nanog mRNA.
Enhancing Brf1 expression does not compromise mESC pluripo-
tency but does preferentially regulate mesendoderm commitment
during differentiation, accelerating the expression of primitive
streak markers. Together, these studies demonstrate that FGF sig-
nals use targeted mRNA degradation by Brf1 to enable rapid post-
transcriptional control of gene expression in mESCs.
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AU-rich element mRNA-binding proteins (AUBPs) representan important class of regulators required for the proper
development of embryonic and adult tissues in the mouse (1),
but whether they have developmentally important roles in mouse
embryonic stem cells (mESCs) remains unclear. A recent pro-
teomic survey identified more than 500 mRNA-binding proteins
in mESCs, several of which are AUBPs (2). Independent of the
micro-RNA pathway, AUBPs are known regulators of splicing,
mRNA stability, translational efficiency, and RNA transport (3),
and could provide an additional layer of developmental regulation
that complements other pluripotency and self-renewal mecha-
nisms. AUBPs are essential in many developmental systems, such
as during hematopoiesis, neurogenesis, germ cell commitment, and
placental morphogenesis (4–6). Their absence or misregulation can
be lethal and often promotes disease progression (7–9). Despite
growing interest in the many functions of AUBPs, their regulation
and function in mESCs remains poorly understood.
The expression and activity of AUBPs is known to be regu-
lated by growth factor signaling in many cellular contexts (10,
11). In mESCs, the FGF/Erk MAP kinase signaling pathway is
a central regulator of self-renewal, pluripotency, and differenti-
ation (12, 13). Although much is known about the developmental
effects of FGF/Erk MAP kinase signaling inhibition or activation
(14, 15), the regulatory mechanisms used downstream of Erk1/2
often remain unclear. Various transcriptional, posttranscriptional,
and posttranslational mechanisms are engaged to regulate target
genes (16). As part of this signaling cascade, AUBPs could me-
diate rapid signaling-dependent responses, but this potential role
has not been investigated.
Here, we show that the expression of Brf1 (zfp36l1) is regu-
lated by FGF/Erk MAP kinase signaling in both pluripotent and
differentiating mESCs. Brf1 is a member of the Zfp36 AUBP
family that plays critical roles throughout mouse development.
Without Brf1, embryos die in utero at approximately embryonic
day 10.5 (E10.5) as a result of allantoic, placental, and neural
tube defects (9), and its absence in adults promotes leukemia
(17). In mESCs, Brf1 binds AU-rich sequences in many pluri-
potency-associated mRNAs, including Nanog, to regulate their
localization and abundance. This regulation broadly perturbs the
core transcription factor network without inducing differentiation,
but compromises the capacity to self-renew. In differentiation-
stimulating conditions, Brf1 enhances the expression of primitive
streak markers, indicating an accelerated commitment to mesen-
doderm. Together, these data identify targeted mRNA degrada-
tion by Brf1 as a mechanism through which the biology of mESCs
is regulated and controlled by FGF/Erk MAP kinase signals.
Results
Erk MAP Kinase Signaling Regulates the Expression of Zfp36 AUBPs.
AUBP expression in mESCs has been documented by several
groups (2, 9, 18). The known sensitivity of AUBPs to growth
factors suggested that these proteins could be regulated by FGF/
Erk MAP kinase signaling (11, 19). To explore this potential
regulatory connection, we first profiled the transcriptome of E14
mESCs using high-throughput sequencing to determine which
AUBPs are actively expressed (Fig. 1A and Dataset S1). We
identified several classes of AUBPs, including (i) members of the
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Zfp36 protein family [TTP (zfp36), Brf1 (zfp36l1), and Brf2
(zfp36l2)], which are known to play critical roles during hema-
topoiesis by destabilizing Cytokine and Notch-Delta signaling-
associated mRNAs; (ii) members of the Hu protein family [HuR
(elavl1), HuB (elavl2)], which stabilize their mRNA targets and
are known to actively regulate germ cell development; and (iii)
Auf1 (hnrnpd), which can stabilize or destabilize mRNA and
modulate inflammation in the adult mouse (20).
To determine whether any of the detected AUBPs was regu-
lated by FGF/Erk MAP kinase signaling, we measured changes
in their expression in response to pharmacological inhibitors of
MEK1/2. We discovered that TTP and Brf1 responded strongly
to MEK1/2 inhibition, with mRNA levels down-regulated greater
than twofold after 5 and 10 h (Fig. 1B). Brf2, Auf1, and KHSRP
mRNA levels were also slightly down-regulated. Interestingly,
three out of five of these responding genes are members of the
Zfp36 protein family (Fig. 1B, red bracket).
Changes in Erk MAP Kinase Signaling Lead to Transient and Sustained
Zfp36 Responses.We explored the regulatory connection between
Zfp36 AUBPs and FGF/Erk MAP kinase signaling further by
measuring how TTP, Brf1, and Brf2 responded to short and long
periods of MEK1/2 inhibition (Fig. 2A). Incubation with MEK1/2
inhibitor resulted in a rapid reduction in TTP, Brf1, and Brf2
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Fig. 1. Erk MAP kinase signaling regulates AUBP expression in mESCs. (A) Distribution of average transcript abundances (FPKM) from two total RNA bi-
ological replicates. Highlighted are notable mESC pluripotency and differentiation genes (gray triangles), which were used to distinguish actively expressed
genes (mean FPKM ≥ 5, 7,194 genes) from the gene expression background (mean FPKM < 5, 11,119 genes). FPKM = 5 denoted by red dashed line. Well-
characterized and actively expressed AUPBs are highlighted (orange triangles). (B) Profiling changes in AUBP expression using RT-qPCR in response to
a pharmacological inhibitor of MEK1/2 (CI-1040/PD184352) after 5 and 10 h. Members of the Zfp36 family are highlighted in the red bracket.
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Fig. 2. FGF/Erk MAP kinase signaling regulates the expression of Zfp36 RBPs. (A) Cartoon depicting the potential relationship between FGF/Erk MAP kinase
signaling and AUBP expression. Whereas the addition of Fgf4/heparin activates the FGF/Erk MAP kinase pathway, culturing cells with 5 μM PD184352/CI-1040
inhibits Erk1/2 activation. (B) A 30-h RT-qPCR time course of TTP, Brf1, and Brf2 mRNA level changes in response to MEK1/2 pharmacological inhibitors (±SEM;
n = 3 for all time points), and (C) corresponding Western blots. (D) Western blot staining for Erk1/2 and phospho-Erk1/2 (Thr202/Tyr204) showing pathway
activation in cells stimulated with 10 ng/mL FGF4 plus 10 μg/mL heparin for 15 min. (E) Changes in TTP, Brf1, and Brf2 after 5-h incubation with or without
FGF4/heparin as indicated (±SEM; n = 3). (F) Western blot profiling of changes in TTP, Brf1, and Brf2 protein level in fgf4−/−mESCs after stimulation with FGF4/
heparin for 5 h. To compare changes in intracellular localization, proteins were harvested sequentially as cytoplasmic (cyto) or nuclear (nuc) fractions, with
β-tubulin and TATA-binding protein serving as localization controls. Also see Fig. S1 A–D.
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mRNA level as gauged by reverse transcription–quantitative
PCR (RT-qPCR) (Fig. 2B). Brf1, Brf2, and, to a lesser extent,
TTP mRNA level changes were significant within 1 h of inhibitor
treatment (Fig. S1A) and continued to decrease after 7.5 h of in-
hibition (Fig. 2B). However, after 10 h, TTP and Brf2 mRNA ex-
pression recovered, whereas Brf1 expression remained suppressed
(Fig. 2B). Because the pharmacological inhibitor provides con-
tinuous suppression of Erk MAP kinase signaling (Fig. 2 and Fig.
S1B), these data indicate that TTP and Brf2 mRNA respond
only transiently (t < 10 h) to changes in Erk MAP kinase sig-
naling, whereas Brf1 mRNA maintains a sustained response to
the level of Erk MAP kinase signaling.
Protein level changes were also rapid, with a 30% reduction in
TTP and a 50% reduction in Brf1 within 1.5 h of inhibitor
treatment (Fig. 2 and Fig. S1C). However, whereas Brf1 protein
levels continued to fall for the remainder of the time course,
reaching ∼10-fold less protein by 30 h, TTP protein levels re-
covered and increased above DMSO-treated controls (Fig. 2C).
These data indicate that the regulation of TTP protein becomes
distinct from the regulation of TTP mRNA at later times
(compare Fig. 2 B and C). We note that, in other cellular con-
texts, direct phosphorylation of TTP protein by Erk1/2 has been
shown to reduce its stability (10). Furthermore, Zfp36 AUBPs
also contain AU-rich sequences in their own mRNAs, which
enable direct autoregulation and cross-regulation (Fig. 2 and Fig.
S1D). These mechanisms could explain why TTP protein and
mRNA levels respond differently after prolonged MEK1/2 in-
hibition. In contrast, Brf2 protein levels were much less affected,
dropping slightly at 10 h, and then recovering at later time
points. Thus, at both the mRNA and protein levels, Brf2
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Fig. 3. Brf1 expression compromises mESC self-renewal. (A) Changes in Brf1 expression after LIF removal (blue line; light blue bounding boxes at each time
point represent ±SEM; n = 3). The effect of FGF or Erk MAP kinase signaling inhibition on Brf1 expression at each time point is indicated (white and black bars,
resulting from a 3-h inhibitor treatment) (±SEM; n = 3). (B) Changes in FGF4, FGF5, FGFR1, Spred2, and Spry2 mRNA expression after LIF removal (±SD; n = 2).
(C) Brf1 expression was profiled in E14 carrying a CMV-H2B-YFP expression cassette (Brf11×), Brf11× treated with Brf1 siRNAs, and E14 carrying a CMV-Brf1/
T2A/H2B-YFP expression cassette (Brf14×). A Western blot of Brf1 protein shows that siRNA knockdown reduced Brf1 expression by 75% after 36 h, and stable
CMV-driven Brf1 expression increases Brf1 protein levels by fourfold relative to Brf11×. Chemiluminescent intensities were normalized to Gapdh signal as
loading control. (D) Changes in self-renewal of Brf14× relative to Brf11×. Differences in proliferation rate were gauged by changes in the ratio of YFP(+)
transgene-expressing cells to YFP(−) wild-type cells. For t = 48 and 96 h (±SEM; n = 4). For t = 120 and 144 h (±SEM; n = 3). (E) Changes in the expression of
core pluripotency genes via RT-qPCR after Brf1 siRNA knockdown in Brf11× (gray bars) or enhanced Brf1 expression in Brf14× (blue bars) over 36 h (±SEM; n =
2). (F) Profiling changes in the expression of core pluripotency genes via RT-qPCR during the early stages of differentiation (15% serum, without LIF) in Brf11×
treated with Brf1 siRNAs (dashed black line), Brf11× (solid black line), and Brf14× (solid blue line) (±SEM; n = 2).
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responds more weakly to these perturbations (compare Fig. 2 B
and C). These results indicate that AUBP levels respond to
changes in Erk MAP kinase signaling with different kinetics.
To further validate these findings, we checked whether up-
regulating FGF signaling could produce opposite results to in-
hibition (Fig. 2A). We added FGF4/heparin to fgf4−/− R1 mESCs
(strain FD6), to activate Erk MAP kinase signaling (Fig. 2D)
(21). TTP, Brf1, and Brf2 mRNA levels increased within 5 h of
ligand addition, with similar changes at the protein level (Fig. 2 E
and F). These changes occurred specifically within the cyto-
plasmic compartment, consistent with a role for these AUBPs in
regulating targeted degradation of mature mRNAs (Fig. 2F).
Together, these results indicate Zfp36 protein expression responds
rapidly to both increases and decreases in FGF/Erk MAP kinase
signaling activity, leading to both transient (TTP, Brf2) and sus-
tained (Brf1) regulatory responses.
Enhancing Brf1 Compromises mESC Self-Renewal. Among the Zfp36
AUBPs, FGF/Erk MAP kinase signaling most strongly regulated
the expression of Brf1 in pluripotent conditions (Fig. 2). During
differentiation, Brf1 regulation was also dynamic and continued
to be regulated by FGF/Erk MAP kinase signaling (Fig. 3A). The
approximately twofold reduction in Brf1 expression over 4 d of
LIF withdrawal (Fig. 3A) tracked concomitant changes in FGF4
expression (Fig. 3B), and the down-regulation of the Erk MAP
kinase target genes Spred2 and Spry2 (Fig. 3B).
To determine the functional effect of Brf1 on pluripotent and
differentiating cells, we perturbed Brf1 expression using siRNAs,
which produced an approximately fourfold decrease in Brf1
protein relative to wild type. We also created stable transgene-
mediated overexpression cell lines, which increased Brf1 protein
levels approximately fourfold above wild-type levels (Fig. 3C).
For transgene expression in mESCs, clones expressing H2B-YFP
(Brf11×) or Brf1-T2A-H2B-YFP (Brf14×) were derived for these
studies. Of these, one control Brf11× clone that expressed wild-
type levels of Brf1 protein, and one Brf14× clone expressing
approximately fourfold more Brf1 protein, was chosen for
further analysis.
To quantify changes in mESC self-renewal brought about by
Brf1 overexpression, we cocultured YFP(+) Brf14× clones with
wild-type YFP(−) E14 mESCs. In this assay, any change in self-
renewal ability manifests as changes in relative proliferation rate,
and hence, a change in the YFP(+)/YFP(−) ratio (22). Com-
pared with Brf11×, cocultures with Brf14× exhibited a significant
proliferation defect, with the YFP(+)/YFP(−) ratio reduced by
∼20% every 48 h (Fig. 3D). In these cells, the expression of
several core pluripotency genes is altered (Fig. 3E). However,
most remain pluripotent in conditions with LIF plus serum (see
below). Removing LIF rapidly initiates differentiation, and during
the first 48 h, Brf1 siRNA knockdown in Brf11× or Brf1 over-
expression in Brf14× produced only modest effects on the rate at
which some markers of pluripotency were down-regulated (Fig. 3F).
Enhancing Brf1 Expression Accelerates Mesendoderm Differentiation.
In contrast to the mild effect of Brf1 expression on the down-
regulation of pluripotency factors (Fig. 3F), the up-regulation of
Mesendoderm Neurectoderm
Primive  EctodermExtra-embryonic
Endoderm
mESCs
(Oct4, Nanog, Rex1)
(Fgf5, Gbx2, Nodal)
(Sox1, Gbx2)
(Dab2, Gata6, Hnf4a)
(T, Gsc, Mixl1, FoxA2)
A
Brf11x
+Brf1 siRNA
Brf14x Brf1
4x
+ Brf1 siRNA
B 15% FBS without LIF, 3 days: (Promotes Mesendoderm Diﬀerenaon)
Fo
ld
 D
iﬀ
er
en
ce
10 0
10 2
10 3
10 1
10 -1
10 -2
Da
b2
G
at
a6
Hn
f4
a
Fo
xA
2 T
G
sc
M
ix
l1
W
nt
3A
N
kx
2-
5
Tb
x6
Tw
ist
N
od
al
Fg
f5
G
bx
2 10 
-1
10 1
10 2
10 0
Fo
ld
 D
iﬀ
er
en
ce
Da
b2
G
at
a6
Hn
f4
a
Fo
xA
2 T
So
x1
Fg
f5
G
bx
2
C N2B27, 3 days: (Promotes Neurectoderm)
D
Brf11x
Brf14x
N2B27 media
Sox1 Protein, 5 days
50
200
250
300
0
150
100
10 2 10 3 10 510 4
Arbitrary Fluorescence Units
Brf11x
Brf14x
2°
only
Co
un
ts
Brf11x
Brf14x
50
100
150
200
0
10 2 10 3 10 4 10 5
Co
un
ts
15% FBS without LIF media
Brachyury (T) Protein, 3.5 days
Brf11x
Brf14x
2° only
Arbitrary Fluorescence Units
Fig. 4. Brf1 expression promotes mesendoderm differentiation. (A) Cartoon diagram showing the developmental potential of mESCs and associated lineage-
specific markers. (B) Brf11× and Brf14× were cultured in mesoderm differentiation media (15% serum without LIF) for 3 d. Fold difference in the expression of
several lineage-specific differentiation markers in Brf14× relative to Brf11× after 3 d of differentiation (±SEM; n = 3). (C) Brf11× and Brf14× were cultured in
neurectoderm differentiation media (N2B27) for 3 d. Fold difference in the expression of several lineage-specific differentiation markers in CMV-Brf1 E14
relative to control E14 after 3 d of differentiation (±SEM; n = 3). (D) (Left) Brachyury immunostain and associated flow cytometry data after 3.5 d of dif-
ferentiation (n = 2,000 cells). (Right) Sox1 immunostain and associated flow cytometry data after 5 d of differentiation (n = 1,500 cells).
Tan and Elowitz PNAS | Published online April 14, 2014 | E1743
D
EV
EL
O
PM
EN
TA
L
BI
O
LO
G
Y
PN
A
S
PL
U
S
differentiation markers is strongly affected by Brf1 (Fig. 4A).
After 3 d of LIF withdrawal, we observed a striking bias in gene
expression when comparing Brf14× to Brf11× cultures. LIF
withdrawal generally promotes mesoderm differentiation (23).
Indeed, Brachyury (T) was up-regulated in differentiating Brf11×
and Brf14× cultures. However, Brachyury expression was 100-fold
greater in the Brf14× cell line (Fig. 4B). Transfecting Brf11×
cultures with Brf1 siRNAs produced the opposite effect, down-
regulating Brachyury expression approximately fourfold relative
to untreated controls (Fig. 4B). Furthermore, siRNAs against
Brf1 could attenuate the up-regulation of Brachyury in Brf14×,
indicating that this regulation resulted specifically from Brf1
overexpression. In agreement with these results, flow cytometry
profiling indicated that a larger fraction of Brf14× cells expressed
Brachyury protein by 84 h compared with Brf11× (Fig. 4D).
These findings were further supported by the up-regulation of
mesendodermal markers Goosecoid (Gsc), Mixl1, and Wnt3A
(Fig. 4B), indicating that Brf1 accelerated commitment to mes-
endodermal fates. Ectoderm markers (Nodal, Fgf5, and Gbx) were
not affected, whereas extraembryonic and definitive endoderm
markers (Gata6, Hnf4a, and FoxA2) showed weaker basal ex-
pression levels that responded differentially to Brf1 (Fig. 4B).
Brf1 expression did not influence neural differentiation. Be-
cause serum inhibits neural differentiation (24), we cultured cells
in N2B27 serum-free media without LIF and BMP4. After 3 d in
this media, most markers of differentiation appeared to be un-
affected by Brf1 (Fig. 4C). For example, Sox1 mRNA and pro-
tein were readily detected, but its expression levels were similar
in Brf11× and Brf14× cultures (Fig. 4 C and D). Interestingly,
even in N2B27, the basal expression of Brachyury was up-regu-
lated in a Brf1-dependent manner. Thus, Brf1 appears to mainly
affect mesendodermal differentiation pathways.
Brf1 Binds Pluripotency-Associated mRNAs. To better understand
the mechanistic basis for these developmental effects, we pro-
filed possible Brf1 mRNA targets in mESCs. To determine
which actively expressed genes are bound by Brf1, we adapted
a previously developed RNA immunoprecipitation sequencing-
based (RIPseq) assay that could selectively enrich target mRNAs
using an affinity-purified polyclonal antibody against Brf1 (Fig.
5A; Materials and Methods) (25). In parallel, we performed a
negative control using a nonspecific rabbit IgG. RNA from sam-
ples and controls were then processed and analyzed using high-
throughput sequencing.
To provide a quantitative measure of antibody-mediated en-
richment, we computed a statistic, denoted ERIP for each actively
expressed transcript (Materials and Methods). ERIP represents the
amount of mRNA coprecipitated with Brf1 protein over non-
specific background levels (Materials and Methods). Genes with
high ERIP values were more likely to have AU-rich elements
(AREs) in their 3′-UTR (Fig. 5B). For example, considering the
transcripts most enriched by Brf1 immunoprecipitation (positive
outliers, ERIP > 1.226, 418 genes), 25.1% contained the minimal
full consensus ARE and 60.0% contained the minimal partial
consensus ARE. These percentages represent a threefold to
fourfold increase in ARE abundance relative to their frequency
among all protein coding genes (Table S1 and Datasets S2–S4).
Moreover, several of the most highly enriched target genes were
previously characterized as direct targets of Zfp36 proteins (e.g.,
Ier3, Mllt11, and Pim3), including Zfp36 proteins themselves
(26, 27). Interestingly, based on our definition of the minimal
ARE element, many highly enriched target genes do not contain
consensus AREs. However, the existence of noncanonical (al-
though still poorly characterized) AU-rich sequences has been
documented and could explain the enrichment of these mRNAs
(28). Thus, the RIPseq assay can selectively enrich for mRNAs
containing AREs.
Several pluripotency-associated factors were detected in the
Brf1-RIP fraction, potentially explaining the developmental effects
of Brf1 overexpression. For example, the core pluripotency regu-
lators Nanog (ERIP = 0.58) and Klf2 (ERIP = 7.15) were both
within the top quartile of enriched targets. Nanog broadly inhibits
mESC differentiation, and its expression is reduced as cells lose
pluripotency and commit to extraembryonic and somatic cell line-
ages in culture (29, 30). Klf2, along with Klf4 and Klf5, inhibits
mesendoderm differentiation. Knockdown of Klf factors up-
regulates primitive streak markers, as well as Cdx2, a gene
expressed in trophectoderm and extraembryonic mesoderm (31).
Also consistent with a role for Brf1 in promoting mesen-
doderm, the pluripotency factors Kdm4c (ERIP = 0.63) and Zfp143
(ERIP = 0.99) were enriched in the RIPseq assay. Knockdown of
the lysine methyl-transferase Kdm4c is known to up-regulate mes-
endoderm and extraembryonic mesoderm markers (32). Zfp143
coordinates with Oct4 to transcriptionally activate Nanog. siRNA
knockdown of Zfp143 rapidly initiates differentiation and pro-
motes the expression of Fgf5, Cdx2, and Cdh3, which are expressed
in trophectoderm and cells that commit to extraembryonic me-
soderm (33). Understanding the regulation of these mRNAs may
provide additional mechanistic insights into the Brf1-dependent
control of gene expression in mESCs.
Brf1 Binds Nanog mRNA in Vitro. To corroborate these RIPseq
results, we assayed for direct binding of Brf1 to an enriched
mRNA, in this case, Nanog (Fig. 6A). Previous work has shown
that Nanog is strongly regulated by FGF/Erk MAP kinase sig-
naling (34), and these effects are mediated, in part, by direct
regulation of the Nanog promoter (35). Posttranscriptional reg-
ulation by Brf1 would provide an alternative mechanism to re-
press Nanog expression.
We conducted a protein pull-down assay using RNA as bait
(Fig. 6B, Left). Wild-type RNA and variants with ARE sequence
mutations were expressed in vitro and hybridized at their 3′ ends
to DNA oligonucleotides coupled to magnetic microbeads. These
RNA–microbead conjugates were then incubated with crude cyto-
plasmic protein extracts, and all proteins capable of binding
hybridized RNAs were magnetically isolated and purified for
further analysis.
We used the 3′-UTR sequence of IL-2 as a positive control,
because it contains clusters of ARE sequences that are bound
and regulated by Zfp36 AUBPs (Fig. S2A) (36). Western blots
showed that Brf1 could be purified from mESC lysates using
a conjugated wild-type IL-2 sequence, but not using a mutant
IL-2 lacking known AREs (Fig. 6B). Two Brf1 bands of different
sizes were detected, possibly indicating the purification of dif-
ferent posttranslationally modified forms of Brf1 (Fig. 6B).
We next repeated the assay using Nanog mRNA as bait. The
3′-UTR of Nanog mRNA is ∼1 kb and contains three potential
ARE elements: one full consensus (site 1 in Fig. 6A) and two
partial nonconsensus sequences (sites 2 and 3 in Fig. 6A).
Western blotting of these protein pull downs indicated that Brf1
bound to wild-type Nanog mRNA (Fig. 6B). Mutating the full-
consensus ARE (site 1) significantly reduced Brf1 binding. Re-
moving the remaining two partial nonconsensus AREs (sites 2
and 3) did not appear to further reduce the Brf1 signal. In
contrast, the presence or absence of AREs did not affect the
binding of other RNA-binding proteins (RBPs). For example,
addition of an androgen receptor 3′-UTR sequence, which
contains a poly(C) RNA-binding protein 1 (PCBP1) site, to
Nanog mRNA permitted isolation of PCBP1 protein (Fig. S2B).
This binding was not affected by the presence or absence of
Nanog’s AREs. In contrast, a Nanog mRNA containing only
a 120-nt poly(A) without a PCBP1 site did not bind PCBP1
protein. Together, these results confirm that Brf1 binds specifi-
cally to Nanog mRNA in an ARE-dependent manner.
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FGF/Erk MAP Kinase Signaling Regulates Nanog mRNA Half-Life
Through its AREs. To understand how Brf1 binding impacts
Nanog expression, we measured the Nanog mRNA half-life, with
or without AREs, and with or without FGF signaling, in fgf4−/−
mESCs (Fig. 6C). We determined that the half-life of Nanog
mRNA is 2.5 ± 0.4 h (±SEM) without FGF4/heparin and 1.5 ±
0.3 h (±SEM) with Fgf4/heparin (Fig. 6C, Top). However,
removing all 3′-UTR ARE sites [ΔARE (1–3)] protected Nanog
from increased degradation by FGF signaling (Fig. 6C, Middle),
indicating that FGF destabilizes Nanog mRNA through its
AREs. Additionally, when we analyzed H2B-YFP mRNA as a
negative control, we observed no effect of FGF signaling on half-
life (Fig. 6C, Bottom).
Unexpectedly, mutant Nanog mRNA [ΔARE (1–3)] exhibited
a shorter half-life than wild type (2 h instead of 2.5 h; Fig. 6C). In
the absence of FGF, we would have expected that the half-life of
mutant and wild-type mRNAs to be the same. However, it is
possible that Nanog’s AREs are subject to regulation by other
protein factors that have different effects. For example, AREs
could associate with stabilizing AUBPs, such as HuR, whose
activity is independent of FGF/Erk MAP kinase signaling in
mESCs (Fig. 1C). Primary sequence changes may have also af-
fected mRNA stability independent of any particular AUBP.
Despite this difference, the above data clearly show that Nanog’s
AREs are necessary for any posttranscriptional regulation by FGF.
To show that FGF regulates Nanog through Brf1, we con-
ducted an epistasis test in fgf4−/− R1 mESCs. We transfected
mock or Brf1 siRNAs, and measured changes in Brf1 and Nanog
mRNA level both in the presence and absence of FGF4/heparin.
Relative to siRNA control (Fig. 6D, first column), Brf1 siRNAs
caused a slight (∼10%) down-regulation of Brf1 and a corre-
sponding increase in Nanog mRNA levels (Fig. 6D, second col-
umn). These data indicate that Brf1 is expressed, albeit at a
lower level, even when FGF signaling is absent (Fig. S2C) and
that alternative pathways support its basal expression. We con-
firmed that FGF signaling remains the dominant regulator of
Erk in mESCs (Fig. 2D) and that Erk MAP kinase signaling is
the main driver of Brf1 expression (Fig. S2C).
Addition of FGF4/heparin ligand increased Brf1 and de-
creased Nanog by greater than twofold within 5 h (Fig. 6D, third
column). In agreement with its role as a regulatory intermediate,
the presence of Brf1 siRNAs reduced this regulation, yielding
a smaller up-regulation of Brf1 and a smaller down-regulation of
Nanog (Fig. 6D). We note that the inability of Brf1 siRNAs to
fully block the down-regulation of Nanog can be partly explained
by its limited knockdown efficiency (∼75%) (Fig. 3C) but could
also reflect Brf1-independent regulatory mechanisms.
FGF/Erk MAP kinase signaling thus regulates the dynamic
expression of Zfp36 AUBPs in mESCs, which in turn affect the
stability of key mRNA targets. In particular, we show that Brf1
(zfp36l1) has the capacity to broadly impact the regulation of
core pluripotency-associated transcription factors, down-regulate
self-renewal, and promote lineage-specific commitment during
differentiation. In this way, Brf1 provides a specific molecular
link between FGF/Erk MAP kinase signaling and the regulation
of gene expression in mESCs.
Discussion
AUBPs modulate developmental gene expression in response to
intercellular and intracellular signals. Some specific examples of
this regulation include the repression of Notch1 in response to
PI3K/Erk MAP kinase signals during T-cell development (17),
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repression of TNF-α in response to p38/Erk MAP kinase signals
during inflammation (37), and the stabilization of p21 in re-
sponse to ATR/ATM kinase activation after DNA damage (38).
Here, we demonstrate AUBPs mechanistically connect FGF/Erk
MAP kinase signaling to the regulation of pluripotency, self-re-
newal, and differentiation in mESCs. More specifically, control
over Brf1 expression rapidly regulates the expression of key
pluripotency-associated genes, reduces the capacity to self-renew,
and enhances mesendoderm differentiation upon LIF withdrawal.
Why has Brf1 been selected for implementing FGF-dependent
cellular responses in mESCs? One possibility is that, owing to its
rapid transcriptional response to FGF signaling and its short
protein and mRNA half-life (∼1.5 and ∼1 h, respectively), Brf1 is
capable of tracking dynamic changes in Erk MAP kinase activity.
Brf1 directly affects mRNA abundance and provides stem cell
populations with a mechanism to quickly respond to changes
in FGF signaling, without necessarily altering underlying tran-
scriptional states. However, the benefit of these dynamical prop-
erties to the biology of pluripotent or differentiating mESCs still
remains unclear. Brf1 also provides a regulation that is similar to
miRNAs, which also provide mRNA-level repression while main-
taining flexibility in target selection. Interestingly, Zfp36 AUBPs
and miRNAs are known to cooperate in regulating some mRNA
targets (39), indicating a potential point of convergence between
these two regulatory mechanisms. Future work will address why
this system is particularly well adapted to serve as a regulator in
mESCs, and as a mediator of FGF/Erk MAP kinase signaling.
Whether Brf1 plays a similar role in the embryo is unclear. We
note that the regulatory effects of Brf1 in cell culture mimic the
developmental response to FGF/Erk MAP kinase signaling at
different stages of embryonic development. For example, FGF4
signaling promotes extraembryonic endoderm differentiation
in the inner cell mass partly by destabilizing the expression of
pluripotency genes (40). Brf1 may participate in this process by
repressing Nanog and other pluripotency regulators. At a slightly
later developmental stage, and one that is more relevant to
mESCs, both FGF4 and FGF8 are required for mesoderm in-
duction (41, 42). The expression of Brachyury, a regulator of
mesoderm morphogenesis, is enhanced by FGF4 and FGF8
signaling through unknown mechanisms (43). Our results show
that Brf1 expression during differentiation in mESCs similarly
enhances Brachyury and other primitive streak markers. This
regulatory connection could explain why Brf1 knockout mice
also exhibit the same gross defects in chorio-allantoic fusion,
neural tube closure, and placental organization at midgestation
(E11) as FGFR2 knockouts, an indication of shared regulation and
function (9, 44). Although the regulation of FGF/Erk MAP kinase
signaling likely differs between the embryonic and cell culture
context, these observations implicate Brf1 as an important FGF/Erk
MAP kinase-inducible regulator of development in both systems.
Materials and Methods
RT-qPCR Experiments. Total RNA was harvested from samples and controls
using Qiazol Reagent (Qiagen) or an RNeasy Mini Kit (Qiagen). RT of iso-
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lated mRNA into cDNA was accomplished using iScript cDNA Synthesis Kit
(Bio-Rad). A single qPCR reaction was composed of 0.5 μL of cDNA, primers or
primers with probes, and qPCR reaction mix (diluted to a final volume of
10 μL). For qPCR experiments using TaqMan/hydrolysis probes (5′ dye: fluo-
rescein amidite; 3′ quencher: Zen/Iowa Black FQ), cDNAs were profiled
with SsoFast Probes Supermix Reagent (Bio-Rad) using the manufacturer-
recommended protocol. In brief, we used a two-step thermocycling protocol
(an initial 30-s 95 °C melt, followed by 40 cycles of 5-s 95 °C melt and 10-s 60 °C
anneal/extend). For mRNA half-life qPCR experiments using primers only,
cDNAs were profiled with SsoFast EvaGreen Supermix Reagent (Bio-Rad)
using the manufacturer-recommended protocol. In brief, we used a two-step
thermocycling protocol (initial 30-s 95 °C melt, followed by 40 cycles of 5-s 95 °C
melt and 10-s 55 °C anneal/extend), terminating with a postamplification
melt curve analysis (initialized at 60 °C, and increased at 0.5 °C increments
every 10 s to 95 °C). All measurements were made using a Bio-Rad CFX96
Real-Time PCR System (Bio-Rad). See primer and probe characterization
(Table S2).
Cell Lines and Cell Culture. fgf4−/− mESCs (strain FD6) were a kind gift from
Dr. Angie Rizzino (University of Nebraska Medical Center, Omaha, NE).
Cultures were routinely passaged in complete ES culture medium [15%
(vol/vol) FBS, 1,000 U/mL LIF, nonessential amino acid (NEAA), sodium py-
ruvate, and β-mercaptoethanol (βME) in DMEM] in the absence of feeders.
Mesoderm differentiation media contained the following: 15% (vol/vol) FBS,
NEAA, sodium pyruvate, and βME in DMEM (23); neurectodermal differen-
tiation media contained the following: N2B27 serum free media (45).
Reagents, Antibodies, Signaling Inhibitors, and siRNAs. Reagents included the
following: Qiazol reagent (Qiagen); iScript Kit (Bio-Rad); SsoFast Probes
Supermix (Bio-Rad).
Antibodies included the following: mouse monoclonal (L34F12) anti-p44/
p42 (Cell Signal; catalog #4696; 1:2,000); rabbit monoclonal (D13.14.4E) anti-
phospho-p44/p42 (Cell Signal; catalog #4370; 1:2,000); mouse anti-TBP
(Abcam; catalog #ab818; 1:1,000); rabbit anti–β-Tubulin (Abcam; catalog
#ab6046; 1:1,000); rabbit polyclonal anti-Brf1/2 (Cell Signal; catalog #2119;
1:1,000); rabbit anti-Zfp36 (Protein Tech Group; catalog #12737-1-AP; 1:500);
rabbit anti-hnRNP E1 (Cell Signal; catalog #8534; 1:500); goat anti-Brachyury
(R&D Systems; catalog #AF2085; 1:200); rabbit anti-Sox1 (GeneTex; catalog
#GTX62974; 1:200); mouse anti-Gapdh (Abcam; catalog #ab8245; 1:5,000).
Signaling inhibitors included the following: CI-1040 (also known as
PD184352; Axon; 5 μM); PD173074 (Sigma; 100 ng/mL).
siRNAs included the following: TTP siRNA (Santa Cruz Biotechnology; 10
nM); Brf1 siRNA (Santa Cruz Biotechnology; 10 nM); Brf2 siRNA (Santa Cruz
Biotechnology; 10 nM); All Stars Negative Control siRNA (Qiagen; 10 nM).
Measurement of mRNA Half-Life. mESC cultures were cotransfected with
a reverse Tet (rTet) expression plasmid (PGK-H2B-mCherry/T2A/rTet) and
either CMV(2xTetO)-H2B-YFP or CMV(2xTetO)-Nanog with and without ARE
site mutations at 19:1 ratio by mass. Culture media was then transitioned to
media containing FGF4 and heparin (10 ng/mL and 10 μg/mL, respectively) or
PBS to determine the regulatory effect of ERK MAP kinase signaling in fgf4−/−
cells. To stop transcription from the CMV-TO promoter, doxycycline was
added to a concentration of 1 μg/mL to permit binding of rTet to TetO
sequences. Changes in the abundance of H2B-YFP or Nanog mRNA relative
to Gapdh, Sdha, and Tbp housekeeping genes was measured using RT-qPCR.
To distinguish from endogenous Nanog mRNA, we developed a primer set
that specifically recognizes the 5′-UTR of Nanog expressed from the
CMV(2×TetO) promoter.
Isolation of RBPs from Crude Cytoplasmic Lysates. IL-2 and Nanog RNAs were
produced in vitro using T7 Ampliscribe (Epicentre Technologies). These RNAs
were then hybridized to biotin-DNA oligonucleotides at their 3′ end. Two
hundred picomoles of IL-2 or Nanog RNA were used for 250 pmol of biotin-
DNA oligonucleotide. Hybridization reactions were added to 1 mg of
streptavidin magnetic agarose beads (New England Biolabs). Crude cyto-
plasmic extracts used for protein pull-down assays were obtained using
NE-PER reagents (Thermo Scientific). RNA/DNA–bead conjugates were in-
cubated in crude cytoplasmic extract for 1 h at 4 °C, washed five times with
Binding Buffer (20 mM Tris·HCl, pH 7.5, 50 mM KCl, 1 mM EDTA, 1 mM DTT,
0.5% Triton X-100 with RNase inhibitors) and incubated in High Salt Elution
Buffer (Binding Buffer plus 1 M NaCl) to collect RNA-bound protein frac-
tions. Protein pull downs were analyzed via Western blot.
Preparation of Cells for Flow Cytometry. Cultures were harvested with 0.25%
trypsin-EDTA, dispersed into a cell suspension, and added to an equal volume
of 4% formaldehyde. Cells were fixed for 5 min, quenched, and gently
pelleted at 500 × g for 30 s. Supernatants were removed and cell pellets
were resuspended in 2.5 mg/mL BSA in 1× HBSS. The resulting cell suspen-
sions were incubated overnight at 4 °C before flow cytometry analysis. For
antibody-stained cell suspensions, cell pellets containing fixed cells were
resuspended in 10% FBS in PBS to block, gently pelleted, and stained with
appropriate primary and secondary antibodies at 4 °C. Before flow cytometry
analysis, cells were pelleted and resuspended in 2.5 mg/mL BSA in 1× HBSS.
All samples, stained and unstained, were analyzed with a Miltenyi Biotec
VYB flow cytometer. Compensation and background correction were
applied postacquisition.
RNA/RBP Immunoprecipitation and RNA Sequencing. RBP–mRNA complexes
were isolated using a Magna-RIP kit (Millipore). Briefly, cytoplasmic extract
from ∼1 × 107 E14 mESCs was distributed equally among two samples and
two controls. For sample reactions, 5 μg of α-Brf1/2 antibody was used for 50
μL of magnetic protein A/G beads. For control reactions, 5 μg of rabbit IgG
with no immunoreactivity was used for 50 μL of magnetic protein A/G beads.
After stringency washes and proteinase K digestion, RNA was isolated using
Qiazol reagent.
RNA/RBP immunoprecipitation (RIP)-purified RNAs and total RNA from E14
mESCs were prepared for sequencing using a TruSeq RNA Sample Prep kit.
RNAs were fragmented to generate lengths of ∼200 nt, reverse transcribed
with random hexameric primers to generate double-stranded DNA, blunted,
adenylated, and ligated to Illumina sequencing adapters (150 bp). DNA
fragments were gel separated, and all fragments running at 350 bp were
extracted and amplified. Amplified DNA fragments were then sequenced
using an Illumina HiSeq2000.
RNA-Sequencing Analysis Tools and Methods. Raw sequencing reads were
trimmed (of 13 nt from 5′ end) before Bowtie mapping using a mouse
transcript annotation containing only protein coding genes (18,313 genes),
derived from NCBI37/mm9 genome build. Mapping statistics were generated
using eXpress (46). For enrichment analysis, fragments per kilobase exon
per million mapped reads (FPKM) were used as a measure of transcript
abundance (47).
We computed a statistic (ERIP,n) that represents the degree to which the
abundance of the nth transcript is enriched by antibody-mediated RIP. This
statistic uses differences in a transcript’s abundance after Brf1/2 antibody RIP
(mean FPKMBRF,n ) compared with rabbit IgG RIP (mean FPKMIgG,n), nor-
malized by their initial abundance in total RNA before RIP (mean FPKMTotal,n).
This difference was further normalized by a penalty factor (P), which
accounts for a transcript’s tendency to be nonspecifically purified, and is thus
a saturating function of transcript abundance in the IgG control experiment:
ERIP,n =

ABRF,n −AIgG,n

P
,
where
ABRF,n =
mean FPKMBRF,n
mean FPKMTotal,n
,
AIgG,n =
mean FPKMIgG,n
mean FPKMTotal,n
,
P =median

AIgG

+AIgG,n:
Although AIgG,n captures the level of nonspecific association of a transcript
with assay components (i.e., protein A/G beads, rabbit IgG, etc.), nonspecific
association of transcripts with immunoprecipitated RBP/RNA complexes
could not be independently quantified, and could contribute a background
to these ERIP,n values.
High-Throughput Sequencing Data. Raw sequencing data discussed in this
publication were deposited in the National Center for Biotechnology In-
formation Gene Expression Omnibus database (accession no. GSE40104).
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